BiotechTube

VX-147

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glomerulosclerosis, Focal Segmental

Conditions

Glomerulosclerosis, Focal Segmental

Trial Timeline

Jun 8, 2020 → Dec 9, 2021

NCT ID
NCT04340362

About VX-147

VX-147 is a phase 2 stage product being developed by Vertex Pharmaceuticals for Glomerulosclerosis, Focal Segmental. The current trial status is completed. This product is registered under clinical trial identifier NCT04340362. Target conditions include Glomerulosclerosis, Focal Segmental.

What happened to similar drugs?

1 of 2 similar drugs in Glomerulosclerosis, Focal Segmental were approved

Approved (1) Terminated (0) Active (1)
✅DapagliflozinAstraZenecaApproved
🔄sparsentan + IrbesartanTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05955872Phase 1Completed
NCT04340362Phase 2Completed

Competing Products

14 competing products in Glomerulosclerosis, Focal Segmental

See all competitors
ProductCompanyStageHype Score
DapagliflozinAstraZenecaApproved
43
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
CXA-10MedpacePhase 2
32
Sparsentan + Sparsentan + SparsentanTravere TherapeuticsPhase 2
36
sparsentan + IrbesartanTravere TherapeuticsPhase 3
38
RE-021 (Sparsentan) + IrbesartanTravere TherapeuticsPhase 2
29
VoclosporinAurinia PharmaceuticalsPhase 2
21
PraliciguatAkebia TherapeuticsPhase 2
32